These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1990696)

  • 1. Induction of cell-mediated IL-2-activated antitumor responses in conjunction with autologous and allogeneic bone marrow transplantation.
    Slavin S; Ackerstein A; Kedar E; Reich S; Gomez S; Naparstek E; Nagler A; Or R; Weiss L
    Transplant Proc; 1991 Feb; 23(1 Pt 1):802-3. PubMed ID: 1990696
    [No Abstract]   [Full Text] [Related]  

  • 2. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation.
    Tam YK; Klingemann HG
    Biol Blood Marrow Transplant; 1999; 5(4):231-42. PubMed ID: 10465103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in conjunction with autologous bone marrow transplantation.
    Eckerstein A; Slavin S; Weiss L; Naparstek E
    Bone Marrow Transplant; 1990 Jan; 5 Suppl 1():38. PubMed ID: 2317604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2.
    Slavin S; Ackerstein A; Kedar E; Weiss L
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():86-90. PubMed ID: 2390644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study.
    Blaise D; Stoppa AM; Olive D; Brandely M; Tiberghien P; Attal M; Attal J; Reiffers J; Demeocq F; Pico JL
    Bone Marrow Transplant; 1991; 7 Suppl 2():146. PubMed ID: 1878687
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
    Blaise D; Attal M; Reiffers J; Michallet M; Bellanger C; Pico JL; Stoppa AM; Payen C; Marit G; Bouabdallah R; Sotto JJ; Rossi JF; Brandely M; Hercend T; Maraninchi D
    Eur Cytokine Netw; 2000 Mar; 11(1):91-8. PubMed ID: 10705305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT).
    Slavin S; Or R; Kapelushnik Y; Drakos P; Ackerstein A; Vourka-Karussis U; Weiss L; Nagler A
    Leukemia; 1992 Nov; 6 Suppl 4():164-6. PubMed ID: 1434823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of graft versus leukemia effect in bone marrow transplantation: dosage and time schedule dependency of interleukin 2 therapy.
    Charak BS; Brynes RK; Katsuda S; Groshen S; Chen SC; Mazumder A
    Cancer Res; 1991 Apr; 51(8):2015-20. PubMed ID: 2009520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P; Vourka-Karussis U; Weiss L; Slavin S
    J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant granulocyte/macrophage-colony stimulating factor in human and murine bone marrow transplantation.
    Blazar BR; Widmer MB; Kersey JH; Ramsay NK; McGlave PB; Urdal DL; Gillis S; Henney C; Vallera DA
    Behring Inst Mitt; 1988 Aug; (83):170-80. PubMed ID: 3071335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice].
    Xu KL; Ju JP; Pan XY; Du B; Li ZY; Lu QX
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):372-5. PubMed ID: 12941194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunotherapy combining leukemic cell-derived shock protein and dendritic cells applied to leukemic mice following homologous bone marrow transplantation].
    Iuchi Y
    Hokkaido Igaku Zasshi; 2005 Jan; 80(1):149-59. PubMed ID: 15796041
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapeutic aspects of allogeneic peripheral progenitor cells.
    Glass B; Uharek L; Hartung G; Zeis M; Steinmann J; Dreger P; Krönke M; Schmitz N
    Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S3-8. PubMed ID: 9712483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin 2-activated syngeneic bone marrow in mice.
    Agah R; Malloy B; Kerner M; Girgis E; Bean P; Twomey P; Mazumder A
    Cancer Res; 1989 Nov; 49(21):5959-63. PubMed ID: 2790810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms.
    Long GS; Cramer DV; Harnaha JB; Hiserodt JC
    Bone Marrow Transplant; 1990 Sep; 6(3):169-77. PubMed ID: 2252956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.